Everolimus is an oral prescription medication used to treat certain types of cancer, non-cancerous tumors, and to prevent organ transplant rejection. Sold under brand names such as Afinitor, Zortress, and Votubia, everolimus is classified as an mTOR inhibitor, which slows cell growth and suppresses immune system activity.
This article provides a complete overview of everolimus, including its approved uses, how it works, dosage guidelines, common side effects, and what patients should know before starting treatment.
What Is Everolimus?
Everolimus is a targeted therapy that interferes with the mTOR (mammalian target of rapamycin) pathway a key regulator of cell growth, proliferation, and survival. By blocking this pathway, everolimus can:
- Slow the growth of tumors
- Prevent organ rejection in transplant patients
- Reduce abnormal cell development in rare genetic conditions
It is available in tablet form and is typically dispensed by specialty pharmacies due to its complexity and monitoring requirements.
FDA-Approved Uses of Everolimus
Everolimus is approved by the U.S. Food and Drug Administration (FDA) for multiple indications, including both oncology and transplant-related conditions:
1. Cancer Treatment (Afinitor)
- Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer (postmenopausal women, used with exemestane)
- Advanced Renal Cell Carcinoma (RCC)
- Neuroendocrine Tumors of Pancreatic, Gastrointestinal, or Lung Origin
- Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)
- Renal Angiomyolipoma associated with TSC
2. Transplant Rejection Prevention (Zortress)
- Kidney Transplant: Used with other immunosuppressants to prevent rejection
- Liver Transplant: Approved for use in adult liver transplant recipients
- Not approved for heart transplant: Due to increased risk of serious and potentially fatal infections, everolimus is not recommended for heart transplant patients
How Everolimus Works
Everolimus works by inhibiting the mTOR protein, which regulates cell division and immune system responses. In cancer, mTOR inhibition slows tumor growth and angiogenesis (the formation of new blood vessels that feed tumors). In transplant patients, everolimus helps prevent the body from attacking the new organ.
Everolimus Dosage and Administration
Dosage varies depending on the condition being treated and the brand/formulation used. It is critical to follow your healthcare provider’s instructions and never switch brands or formulations without guidance.
General Dosing Guidelines:
- Breast Cancer, RCC, and NETs:
Typical starting dose is 10 mg once daily, taken at the same time each day, with or without food. - TSC-related SEGA or Angiomyolipoma:
Dosing is based on body surface area (BSA) and blood trough levels. - Organ Transplants (Zortress):
Starting dose is usually 0.75 mg twice daily, adjusted based on blood level monitoring and co-administered immunosuppressants.
Important: Everolimus tablets should be swallowed whole, not crushed or chewed. Blood tests are required to monitor drug levels, kidney function, and liver enzymes during treatment.
Common Side Effects of Everolimus
Like all medications, everolimus can cause side effects. Some are mild and manageable, while others may require medical intervention.
Most Common Side Effects:
- Mouth sores (stomatitis)
- Rash or dry skin
- Fatigue
- Diarrhea or constipation
- Cough or shortness of breath
- Increased risk of infections
- Swelling in hands or feet
Serious Side Effects:
- Non-infectious pneumonitis (lung inflammation)
- Kidney or liver function issues
- Delayed wound healing
- Increased cholesterol and blood sugar levels
- Low blood cell counts (anemia, neutropenia, thrombocytopenia)
Let your healthcare provider know immediately if you experience difficulty breathing, persistent cough, fever, or signs of infection.
Important Safety Considerations
- Pregnancy and Breastfeeding: Everolimus may harm an unborn baby and should not be used during pregnancy or breastfeeding.
- Drug Interactions: Everolimus interacts with CYP3A4 inhibitors/inducers (e.g., ketoconazole, rifampin, St. John’s Wort), which may affect drug levels.
- Food Interaction: Grapefruit and grapefruit juice should be avoided as they can interfere with everolimus metabolism.
Access Through Specialty Pharmacies
Everolimus is often dispensed through specialty pharmacies that provide:
- REMS (Risk Evaluation and Mitigation Strategy) support
- Insurance coordination
- Financial assistance resources
- Ongoing counseling for side effect management
Ask your care team to refer you to a pharmacy experienced with oncology or transplant medications.
Conclusion
Everolimus is a versatile and powerful therapy used in cancer treatment and organ transplant care. Understanding how it works, following dosage instructions, and monitoring for side effects are essential to successful treatment. While Zortress is approved for kidney and liver transplants, it is not recommended for heart transplants due to high infection risks.
Whether you are taking Afinitor for cancer or Zortress for transplant support, work closely with your medical team and specialty pharmacy to ensure safe and effective use.
If you have questions about everolimus, speak with your doctor or specialty pharmacist for personalized guidance.
